Depsipeptide to treat T-cell lymphomas

Journal of Drugs in Dermatology, Jan-Feb, 2004

Sponsored by National Cancer Institute (NCI)

This study will test the safety and effectiveness of a new anticancer drug called depsipeptide in treating T-cell lymphomas. Depsipeptide has been shown to kill cancer cells in laboratory studies and to shrink various kinds of tumors in animal models. This study will evaluate the response of T-cell lymphomas to depsipeptide and determine how well patients tolerate the drug over a period of several months.

Condition                    Treatment or Intervention  Phase

Cutaneous T Cell Lymphoma    Drug: Depsipeptide         Phase II
Peripheral T Cell Lymphoma

Study ID Numbers 010049; 01-C-0049

NLM Identifier NCT00007345